Healthy Subjects Clinical Trial
— ALMOND1Official title:
ALMOND1: Nutritional, Organoleptic and Motility Profile of Toritto & Californian Almond
NCT number | NCT03844867 |
Other study ID # | 5037 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 9, 2017 |
Est. completion date | January 1, 2018 |
Verified date | February 2019 |
Source | University of Bari |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The cultivation of almond (Amygdalus communis L.) has always been a hallmark of the
Mediterranean, representing a resource both food and economic. Almonds are high in fat
(55.3%, mainly (39.4%) they consist of MUFA), are an excellent source of vitamin E,
manganese, magnesium, copper, phosphorus, fiber, riboflavin and protein, phenolic and
polyphenolic.
Numerous studies correlate moderate and regular consumption of nuts with an important role in
health. In particular, habitual almond consumption does not lead to weight gain, and their
inclusion in low-calorie diets appears to promote more weight loss than a comparable
carbohydrate-based low-calorie diet. Also, almonds have a low glycemic index and do not
adversely impact insulin sensitivity. So they reduce certain risk factors linked to diabetes
and cardiovascular disease. Almonds are an excellent source of bioavailable α-tocopherol, and
increasing their intake enhances the resistance of LDL against oxidation. In addition, the
polyphenolic constituents of almonds have been characterized recently and found to possess
antioxidant actions. Some studies show as consumption of almonds has been shown to be
associated with lower levels of serum cholesterol and triglycerides thanks of their
poly-unsaturated fatty acids.
Despite Mediterranean countries have dominated world trade for a long time, from the '80
years, Italy underwent a strong production crisis, mainly due to the lack of new plants
conducted according to the most modern techniques of cultivation and competition from other
crops considered more profitable (e.g. wine, horticultural and citrus). The United States, in
particular California, currently control more than a third of the world production of almond,
using different cultivars and agronomic practices, based on more modern systems.
In Apulia, various native cultivars have been developed such as "Filippo Cea", which have
resisted the invasion of the most productive varieties of California.
The aim of the project is to assess the quality and the beneficial effects of almonds,
comparing a local cultivar (Filippo Cea) with an imported (Carmel) one. The study will be
characterized by different phases:
- Organoleptic analysis of the two different cultivars of almonds
- evaluation of gastrointestinal motility after taking the two types of almonds.
Status | Completed |
Enrollment | 84 |
Est. completion date | January 1, 2018 |
Est. primary completion date | September 1, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Healthy volunteers. - Aged 18-80 years old. - Normal and obese subjects. - Able to provide informed consent. Exclusion Criteria: - Refusal to sign the informed consent. - Diagnosis of organic diseases including neoplastic inflammatory illness or cardiovascular diseases. - Hypersensibility to almonds. |
Country | Name | City | State |
---|---|---|---|
Italy | Department of Biomedical Sciences and Human Oncology - Clinica medica "A. Murri" | Bari | BA |
Lead Sponsor | Collaborator |
---|---|
University of Bari |
Italy,
Ahrens S, Venkatachalam M, Mistry AM, Lapsley K, Sathe SK. Almond (Prunus dulcis L.) protein quality. Plant Foods Hum Nutr. 2005 Sep;60(3):123-8. — View Citation
Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, Haight JS, Faulkner D, Vidgen E, Lapsley KG, Spiller GA. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation. 2002 Sep 10;106(11):1327-32. — View Citation
Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL. Lipophilic and hydrophilic antioxidant capacities of common foods in the United States. J Agric Food Chem. 2004 Jun 16;52(12):4026-37. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Organoleptic valuations | Subjects will give a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly. A semiquantitative scale (ranging from 0 to 3, in order of ascertainment for sensations, from lower=0 to higher=3 grade) will be used as markers of visual aspects, olfactory, flavor, mouth tactile sensations. Before each test, and also between the two samples, the mouth will be washed with mineral water. Food, drink, smoking and physical activity will not be allowed before and during the test. | 1 day | |
Primary | Visual Analog Scale | A quantitative visual analogue scale (VAS, ranging from 0 to 100 mm on a horizontal line, from lower to higher ascertainment for sensations) will be used as markers of visual aspects, olfactory, flavor, mouth tactile sensations. | 1 day | |
Primary | Ultrasound examination (gallbladder, stomach) and orocecal transit time) | Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days, in the morning in the fasting state to monitor gastric empting, gallbladder empting (ultrasound) and oro-cecal transit time (H 2 lactulose BT), at baseline and at 5 minutes intervals during the firsts 30 minutes, and at 15 minutes intervals during the remaining 90 minutes, for a total of 2 hours of observations. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds). | 3 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |